AstraZeneca PLC Director/PDMR Shareholding (3828D)
19 Febbraio 2020 - 8:00AM
UK Regulatory
TIDMAZN
RNS Number : 3828D
AstraZeneca PLC
19 February 2020
19 February 2020 07:00 GMT
TRANSACTION BY PERSON DISCHARGING MANAGERIAL
RESPONSIBILITIES
Disclosure under Article 19 of the EU Market Abuse
Regulation
AstraZeneca PLC (the Company) announces that, on 17 February
2020, it was notified by Michel Demaré, a Non-Executive Director of
the Company, that, on 17 February 2020, Mr Demaré purchased 700
Ordinary Shares of $0.25 each in the Company (Shares) at a price of
GBP73.13 per Share.
The attached notification, made in accordance with the
requirements of the EU Market Abuse Regulation, gives further
detail.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Michel Demaré
---------------------------- -------------------------------------
2 Reason for the notification
-------------------------------------------------------------------
a) Position/status Non-Executive Director
---------------------------- -------------------------------------
b) Initial notification Initial notification
/Amendment
---------------------------- -------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------
a) Name AstraZeneca PLC
---------------------------- -------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
---------------------------- -------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-------------------------------------------------------------------
a) Description of the Ordinary Shares of US$0.25 each in
financial instrument, AstraZeneca PLC
type of instrument
Identification code GB0009895292
---------------------------- -------------------------------------
b) Nature of the transaction Share purchase
---------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
GBGBP73.13 700
----------
---------------------------- -------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
---------------------------- -------------------------------------
e) Date of the transaction 17 February 2020
---------------------------- -------------------------------------
f) Place of the transaction XLON
---------------------------- -------------------------------------
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, CVRM, and Respiratory. AstraZeneca
operates in over 100 countries and its innovative medicines are
used by millions of patients worldwide. For more information,
please visit astrazeneca.com and follow us on Twitter @ AstraZeneca
.
Media Relations
Gonzalo Viña +44 203 749 5916
Rob Skelding Oncology +44 203 749 5821
Rebecca Einhorn Oncology +1 301 518 4122
Matt Kent BioPharmaceuticals +44 203 749 5906
Jennifer Hursit Other +44 203 749 5762
Christina Malmberg Hägerstrand Sweden +46 8 552 53 106
Michele Meixell US +1 302 885 2677
Investor Relations
Thomas Kudsk Larsen +44 203 749 5712
Henry Wheeler Oncology +44 203 749 5797
Christer Gruvris BioPharmaceuticals (cardiovascular; metabolism) +44 203 749 5711
Nick Stone BioPharmaceuticals (respiratory; renal) +44 203 749 5716
Josie Afolabi Other medicines +44 203 749 5631
Craig Marks Finance, fixed income +44 7881 615 764
Jennifer Kretzmann Corporate access, retail investors +44 203 749 5824
US toll-free +1 866 381 72 77
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHUWSVRRAUUAAR
(END) Dow Jones Newswires
February 19, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Astrazeneca (LSE:AZN)
Storico
Da Apr 2023 a Apr 2024
